Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations

OBJECTIVES: To compare the cost-effectiveness of first-line gefitinib, erlotinib, afatinib, and osimertinib in patients with non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. METHODS: A systematic review and network meta-analysis (NMA) were conducted to...

Descripción completa

Detalles Bibliográficos
Autores principales: Holleman, Marscha S., Al, Maiwenn J., Zaim, Remziye, Groen, Harry J. M., Uyl-de Groot, Carin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058671/
https://www.ncbi.nlm.nih.gov/pubmed/31541309
http://dx.doi.org/10.1007/s10198-019-01117-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058671/
https://www.ncbi.nlm.nih.gov/pubmed/31541309
http://dx.doi.org/10.1007/s10198-019-01117-3

Ejemplares similares